和黄医药(HCM:NASDAQ)与GSK达成高达12.95亿美元的癌症疗法授权许可协议，股价飙升15%
· seekingalpha.com
和黄医药与GSK就KRAS/EGFR癌症疗法HMPL-A830签署独家授权许可协议，总价值高达12.95亿美元。
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...